

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application Number	To be assigned
		Filed	Herewith
		First Named Inventor	Deanna L. Kroetz
		Art Unit	To be assigned
Examiner Name	To be assigned		
Sheet 1	of 4	Attorney Docket Number	023070-115611US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
K	AA	4,024,258	05/17/1977	Glamkowski et al.	
	AB	5,445,956	08/29/1995	Hammock et al.	
	AC	5,834,293	11/10/1998	Capdevila et al.	
	AD	5,955,496	09/21/1999	Hammock et al.	
	AE	6,150,415	11/21/2000	Hammock et al.	
	AF	6,174,695	01/16/2001	Hammock et al.	
	AG	6,531,506 B1	03/11/2003	Kroetz et al.	
	AH	6,534,282 B2	03/18/2003	Kim et al.	
	AI	2003/0022929 A1	01/30/2003	Ingraham et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ : Kind Code ⁵ (if known)			

Examiner Signature		Date Considered	12-1-05
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60068358 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	Herewith
		First Named Inventor	Deanna L. Kroetz
		Art Unit	To be assigned
		Examiner Name	To be assigned
Sheet	2	of	4
		Attorney Docket Number	023070-115611US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	ABDEL-AAL and HAMMOCK, "Use of Transition-State Theory in the Development of Bioactive Molecules," Chapter 9 in Bioregulators for Pest Control, ACS Symposium Series No. 276 (based on a symposium held Jun. 24-29, 1984), Hedin, ed., American Chemical Society, Washington, D.C., pp. 135-160, 1985.	
	AK	BEETHAM et al., "cDNA Cloning and Expression of a Soluble Epoxide Hydrolase from Human Liver," Archives of Biochemistry and Biophysics, 305 (1), pp. 197-201, Aug. 15, 1993.	
	AL	BLACK et al., "Selective Toxicity of N-Sulfonylated Derivatives of Insecticidal Methylcarbamate Esters," Journal of Agricultural and Food Chemistry, 21 (5), pp. 747-751, Sep./Oct. 1973.	
	AM	BLEE and SCHUBER, "Enantioselectivity of the Hydrolysis of Linoleic Acid Monoepoxides Catalized by Soybean Fatty Acid Epoxide Hydrolase," Biochemical and Biophysical Research Communications, 187 (1), pp. 171-177, Aug. 31, 1992.	
	AN	BONE, Roger C., "Toward an Epidemiology and Natural History of SIRS (Systemic Inflammatory Response Syndrome)," JAMA, 268 (24), pp. 3452-3455, Dec. 1992.	
	AO	BORHAN et al., "Improved Radiolabeled Substrates for Soluble Epoxide Hydrolase," Analytical Biochemistry, 231, pp. 188-200, 1995.	
	AP	CHEUNG et al., "Pesticide Immunoassay as a Biotechnology," Chapter 18 in The Impact of Chemistry on Biotechnology: Multidisciplinary Discussions, ASC Symposium Series No. 362, Phillips et al., eds., American Chemical Society, Washington, D.C., pp. 217-229, 1988.	
	AQ	DEBERNARD et al., "Expression and Characterization of the Recombinant Juvenile Hormone Epoxide Hydrolase (JHEH) from Manduca sexta," Insect Biochemistry and Molecular Biology, 28, pp. 409-419, 1998.	
	AR	DEMLING, Robert H., "The Modern Version of Adult Respiratory Distress Syndrome," Annu. Rev. Med., 46, p. 193-202, 1995.	
	AS	DIETZE et al., "Inhibition of Epoxide Hydrolase from Human, Monkey, Bovine, Rabbit and Murine Liver by trans-3-Phenylglycidols," Comp. Biochem. Physiol., 104B (2), pp. 309-314, 1993.	
	AT	DIETZE et al., "Inhibition of Human and Murine Cytosolic Epoxide Hydrolase by Group-Selective Reagents," Comp. Biochem. Physiol., 104B (2), pp. 299-308, 1993.	
	AU	DIETZE et al., "Spectrophotometric Substrates for Cytosolic Epoxide Hydrolase," Analytical Biochemistry, 216, pp. 176-187, 1994.	
	AV	DIETZE et al., "The Interaction of Cytosolic Epoxide Hydrolase with Chiral Epoxides" Int. J. Biochem., 25 (1), pp. 43-52, 1993.	
	AW	FAHMY and Fukuto, "N-Sulfonylated Derivatives of Methylcarbamate Esters," J. Agric. Food Chem., 29, pp. 567-572, 1981.	
	AX	FAHMY et al., "Selective Toxicity of N,N'-Thiodicarbamates," J. Agric. Food Chem., 26 (3), pp. 550-556, 1978.	
AY	GRANT et al., "Molecular Cloning and Expression of Murine liver Soluble Epoxide Hydrolase," J. Biol. Chem., 268 (23), pp. 17628-17633, Aug. 15, 1993.		


Examiner Signature		Date Considered	12-1-05
-----------------------	--	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	To be assigned	
			Filing Date	Herewith	
			First Named Inventor	Deanna L. Kroetz	
			Art Unit	To be assigned	
			Examiner Name	To be assigned	
Sheet	3	of	4	Attorney Docket Number	023070-115611US


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
6	AZ	GUO et al., "Characterization of a Tobacco Epoxide Hydrolase Gene Induced During the Resistance Response to TMV," The Plant Journal, 15 (5), pp. 647-656, 1998.		
6	BA	HAMMOCK et al., "Epoxide Hydrolases," Chapter 18 in Comprehensive Technology, vol. 3 (Biotransformation), Guengerich, ed., Oxford: Pergamon, pp. 283-305, 1997.		
	BB	HARMS et al., "Expression of a Flax Allene Oxide Synthase cDNA Leads to Increased Endogenous Jasmonic Acid (JA) Levels in Transgenic potato Plants but Not to a corresponding Activation of JA-Responding Genes," The Plant Cell, 7, pp. 1645-1654, Oct. 1995.		
	BC	HITZ et al., "Expression of a $\Delta 6$ -Oleate Desaturase-Related Enzyme from Vernonia galamensis Results in Vernolic Acid Accumulation in Transgenic Soybean," Abstract from the 13th International Symposium of Plant Lipids, Sevilla, Spain, Jul. 5-10, 1998.		
	BD	JOJIMA et al., "Sugar, Glyceryl, and (Pyridylalkoxy)sulfinyl Derivatives of Methylcarbamate Insecticides," J. Agric. Food Chem., 31, pp. 613-620, 1983.		
	BE	KAYSER et al., "Composition of the Essential Oils of Pelargonium sidoides DC. and Pelargonium reniforme Curt," Flavour and Fragrance Journal, 13, pp. 209-212, 1998.		
	BF	KIYOSUE et al., "Characterization of an Arabidopsis cDNA for Soluble Epoxide Hydrolase Gene that is Inducible by Auxin and Water Stress," The Plant Journal, 6 (2), pp. 259-269, 1994.		
	BG	KOZAK et al., "Inhibitors of Alternative Pathways of Arachidonate Metabolism Differentially Affect Fever in Mice," Am. J. Physiol., 275, pp. 1031-1040, 1998.		
	BH	LEE et al., "Identification of Non-Heme Diiron Proteins that Catalyze Triple Bond and Epoxy Group Formation," Science, 280, pp. 915-918, May 8, 1998.		
	BI	MOGHADDAM et al., "Bioactivation of Leukotoxins to Their Toxic Diols by Epoxide Hydrolase," Nature Medicine, 3 (5), pp. 562-566, May 1997.		
	BJ	MOGHADDAM et al., "Novel Metabolic Pathways for linoleic and Arachidonic Acid Metabolism," Biochimica et Bio-physica Acta, 1290, pp. 327-339, 1996.		
	BK	MORISSEAU et al., "Mechanism of Mammalian Soluble Epoxide Hydrolase Inhibition by Chalcone Oxide Derivatives," Archives of Biochemistry and Biophysics, 356 (2), pp. 214-228, Aug. 15, 1998.		
	BL	MULLIN and HAMMOCK, "Chalcone Oxides-Potent Selective Inhibitors of Cytosolic Epoxide Hydrolase," Archives of Biochemistry and Biophysics, 216 (2), pp. 423-439, Jul. 1982.		
	BM	MULLIN, Christopher A., "Adaptive Relationships of Epoxide Hydrolase in Herbivorous Arthropods," Journal of Chemical Ecology, 14 (10), pp. 1867-1888, 1988.		
	BN	MUMBY and HAMMOCK, "Stability of Epoxide-Containing Juvenoids to Dilute Aqueous Acid," Agricultural and Food Chemistry, 27 (6), pp. 1223-1228, Nov./Dec. 1979.		
Q	BO	MURRAY et al., "The Expression of Cytochrome P-450, Epoxide Hydrolase, and Glutathione S-Transferase in Hepatocellular Carcinoma," Cancer, 71 (1), pp. 36-43, Jan. 1, 1993.		

Examiner Signature		Date Considered	12-1-05
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	To be assigned
				Filing Date	Herewith
				First Named Inventor	Deanna L. Kroetz
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	023070-115611US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BP	MURRAY et al., "The Immunohistochemical Localization of Drug-Metabolizing Enzymes in Prostate Cancer," Journal of Pathology, 177, pp. 147-152, 1995.	
	BQ	PINOT et al., "Characterization of Epoxide Hydrolase Activity in Alternaria alternata f. sp. lycopersici. Possible Involvement in Toxin Production," Mycopathologia, 140, pp. 51-58, 1997.	
	BR	PRESTWICH and HAMMOCK, "Rapid Purification of Cytosolic Epoxide Hydrolase from Normal and Clofibrate-Treated Animals by Affinity Chromatography," Proc. Natl. Acad. Sci. USA, 82, pp. 1663-1667, Mar. 1985.	
	BS	STAPLETON et al., "Cloning and Expression of Soluble Epoxide Hydrolase from Potato," The Plant Journal 6 (2), pp. 251-258, 1994.	
	BT	STARK et al., "Comparison of Fatty Acid Epoxide Hydrolase Activity in Seeds from Different Plant Species," Phytochemistry, 38 (1), pp. 31-33, 1995.	
	BU	TATON et al., "Inhibition of Higher Plant 2,3-Oxidosqualene Cyclases by Nitroben-Containing Oxidosqualene Analogues," Phytochemistry, 43 (1), pp. 75-81, 1996.	
	BV	THEYER et al., "Role of the MDR-1-Encoded Multiple Drug Resistance Phenotype in Prostate Cancer Cell Lines," The Journal of Urology, 150, pp. 1544-1547, Nov. 1993.	
	BW	WIXTROM and HAMMOCK, "Membrane-Bound and Soluble-Fraction Epoxide Hydrolases: Methodological Aspects," in Biochemical Pharmacology and Toxicology, Vol. 1: Methodological Aspects of Drug Metabolizing Enzymes, (Zakin and Vessey, eds.), New York: John Wiley & Sons; pp. 1-93, 1985.	
	BX	WIXTROM et al., "Affinity Purification of Cytosolic Epoxide Hydrolase Using Derivatized Epoxy-Activated Sepharose Gels," Analytical Biochemistry, 169, pp. 71-80, 1988.	

Examiner Signature		Date Considered	12-1-05
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	Complete if Known	
				Application Number	10/694,641
				Filing Date	October 27, 2003
				First Named Inventor	Kroetz, Deanna L.
				Art Unit	1614
				Examiner Name	Brian Yong Kwon
				Attorney Docket Number	023070-115611US


U.S. PATENT DOCUMENTS*					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear



FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60511247 v1

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/694,641		
		Filing Date		October 27, 2003		
		First Named Inventor		Kroetz, Deanna L.		
		Art Unit		1614		
		Examiner Name		Brian Yong Kwon		
Sheet	2	of	2	Attorney Docket Number		023070-115611US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AA	CAMPBELL, William B.; "New role for epoxyeicosatrienoic acids as anti-inflammatory mediators"; <u>Trends Pharmacol Sci</u> ; April 2000; pp. 125-127; Vol. 21, No. 4		
	AB	CAMPBELL, William B. <i>et al.</i> ; "Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors"; <u>Circulation Research</u> ; March 1996; pp. 415-423; Vol. 78, No. 3		
	AC	CARRETERO, Oscar A and Suzanne Oparil; "Essential Hypertension: Part I: Definition and Etiology"; <u>Circulation</u> ; 2000; pp. 329-335; Vol. 101		
	AD	CARRETERO, Oscar A and Suzanne Oparil; "Essential Hypertension: Part II: Treatment"; <u>Circulation</u> ; 2000; pp. 448-453; Vol. 101		
	AE	KROETZ, Deanna L. <i>et al.</i> ; "Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney"; <u>Molecular Pharmacology</u> ; 1997; pp. 365-372; Vol. 52		
	AF	MAKITA, Keiko <i>et al.</i> ; "Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet"; <u>J. Clin. Invest.</u> ; 1994; pp. 2414-2420; Vol. 94		
	AG	MAKITA, Keiko <i>et al.</i> ; "Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system"; <u>FASEB J.</u> ; 1996; pp. 1456-1463; Vol. 10.		
	AH	OMATA, K. <i>et al.</i> ; "Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats"; <u>Am. J. Physiol.</u> ; January 1992; pp. F8-F16; Vol. 262, No. 1 Pt. 2		
	AI	SU, Ping <i>et al.</i> ; "Inhibition of renal arachidonic acid ω -hydrolase activity with ABT reduces blood pressure in the SHR"; <u>Am. J. Physiol.</u> ; 1998; pp. R426-R438; Vol. 275.		
	AJ	YU, Z <i>et al.</i> ; "Antihypertensive effect of soluble epoxide hydrolase (sEH) inhibition"; <u>Clinical Pharmacology and Therapeutics</u> ; February 2000; p. 128 (Abstract PII-53); Vol. 67, No. 2		
	AK	ZELDIN, Darryl C.; "Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase"; <u>The Journal of Biological Chemistry</u> ; March 25, 1993; pp. 6402-6407; Vol. 268, No. 9		
	AL	ZOU, A.P. <i>et al.</i> ; "20-HETE is an endogenous inhibitor of the large-conductance Ca^{2+} -activated K^{+} channel in renal arterioles"; <u>Am. J. Physiol.</u> ; January 1996; pp. R228-R237; Vol. 270, No. 1 pt 2.		

Examiner Signature		Date Considered	12-1-05
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.